{"filing":{"accession_number":"0001193125-26-336685","cik":"0001703647","ticker":"KRRO","company_name":"Korro Bio, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"krro-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-20260805.htm"},"events":[{"id":25537,"run_id":23180,"accession_number":"0001193125-26-336685","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.8,"summary":"Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. The pre-funded warrants are immediately exercisable and represent a material dilutive issuance of equity securities that increases the company's outstanding share count.","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26394,"accession_number":"0001193125-26-336685","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. This is a dilutive issuance of equity securities (pre-funded warrants) that will increase the company's outstanding share count and dilute existing shareholders. The warrants are immediately exercisable and represent a material capital structure change for the biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26396,"accession_number":"0001193125-26-336685","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities—specifically pre-funded warrants issued in reliance on Section 3(a)(9) of the Securities Act. The Item 1.01 reference (incorporated by reference) indicates this is part of a capital-raising transaction. The exhibit shows Q2 2026 financial results with cash increasing from $85.2M (Dec 2025) to $137.9M (June 2026), consistent with a dilutive equity issuance to raise capital. This is a material event affecting shareholder equity and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25538,"run_id":23180,"accession_number":"0001193125-26-336685","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Korro issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing cash position of $137.9 million, R\u0026D expenses of $13.6 million, G\u0026A expenses of $6.5 million, and a net loss of $18.9 million.","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26395,"accession_number":"0001193125-26-336685","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Korro issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing key metrics including cash position ($137.9 million), collaboration revenue ($0), R\u0026D expenses ($13.6 million), G\u0026A expenses ($6.5 million), and net loss ($18.9 million). This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26394,"accession_number":"0001193125-26-336685","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. This is a dilutive issuance of equity securities (pre-funded warrants) that will increase the company's outstanding share count and dilute existing shareholders. The warrants are immediately exercisable and represent a material capital structure change for the biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-06"},{"id":26395,"accession_number":"0001193125-26-336685","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Korro issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing key metrics including cash position ($137.9 million), collaboration revenue ($0), R\u0026D expenses ($13.6 million), G\u0026A expenses ($6.5 million), and net loss ($18.9 million). This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-06"},{"id":26396,"accession_number":"0001193125-26-336685","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities—specifically pre-funded warrants issued in reliance on Section 3(a)(9) of the Securities Act. The Item 1.01 reference (incorporated by reference) indicates this is part of a capital-raising transaction. The exhibit shows Q2 2026 financial results with cash increasing from $85.2M (Dec 2025) to $137.9M (June 2026), consistent with a dilutive equity issuance to raise capital. This is a material event affecting shareholder equity and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:59.092090+00:00","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-06"}]}